Yuva Biosciences Files Exempt Offering Notice on March 24, 2026

TL;DR

**Yuva Biosciences is raising capital through an exempt offering.**

AI Summary

Yuva Biosciences, Inc. filed a Form D on March 24, 2026, indicating a notice of an exempt offering of securities. This filing, with SEC Accession No. 0001998258-26-000003, signals that the company is raising capital outside of a traditional public offering, likely from accredited investors. For current or prospective shareholders, this matters because it suggests the company is seeking funding for operations, expansion, or research, which could dilute existing shares if new equity is issued, but also provides capital for growth.

Why It Matters

This filing indicates Yuva Biosciences is raising capital, which can fuel growth but may also lead to dilution for existing shareholders if new equity is issued.

Risk Assessment

Risk Level: medium — The risk is medium because while capital raising is positive for growth, the details of the offering (e.g., equity vs. debt, valuation) are not disclosed, which could impact existing shareholders.

Analyst Insight

An investor should monitor for subsequent filings or press releases from Yuva Biosciences, Inc. that provide details about the terms of this exempt offering, such as the amount raised, the type of securities issued, and the valuation, to assess potential dilution or future growth prospects.

Key Players & Entities

• Yuva Biosciences, Inc. (company) — the filer of the Form D
• 0001998258 (company) — CIK of Yuva Biosciences, Inc.
• 2026-03-24 (date) — the filing and effectiveness date of the Form D

Forward-Looking Statements

• Yuva Biosciences, Inc. will announce the specific terms of its exempt offering within the next 6 months. (Yuva Biosciences, Inc.) — medium confidence, target: 2026-09-24

FAQ

Key Financial Figures

• $1 — enues   No Aggregate Net Asset Value   $1 - $1,000,000 $1 - $5,000,000   $1,000,
• $1,000,000 — No Aggregate Net Asset Value   $1 - $1,000,000 $1 - $5,000,000   $1,000,001 - $5,000,
• $5,000,000 — Net Asset Value   $1 - $1,000,000 $1 - $5,000,000   $1,000,001 - $5,000,000   $5,000,001
• $1,000,001 — e   $1 - $1,000,000 $1 - $5,000,000   $1,000,001 - $5,000,000   $5,000,001 - $25,000,000
• $5,000,001 — $5,000,000   $1,000,001 - $5,000,000   $5,000,001 - $25,000,000 $5,000,001 - $25,000,000
• $25,000,000 — $1,000,001 - $5,000,000   $5,000,001 - $25,000,000 $5,000,001 - $25,000,000   $25,000,001
• $25,000,001 — $25,000,000 $5,000,001 - $25,000,000   $25,000,001 - $50,000,000 $25,000,001 - $100,000,0
• $50,000,000 — 5,000,001 - $25,000,000   $25,000,001 - $50,000,000 $25,000,001 - $100,000,000   $50,000,0
• $100,000,000 — 25,000,001 - $50,000,000 $25,000,001 - $100,000,000   $50,000,001 - $100,000,000   Over $1
• $50,000,001 — 0,000,000 $25,000,001 - $100,000,000   $50,000,001 - $100,000,000   Over $100,000,000   O

Filing Documents

• primary_doc.html (D)
• primary_doc.xml (D) — 7KB
• 0001998258-26-000003.txt ( ) — 8KB

From the Filing

Form D FORM D Notice of Exempt Offering of Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. OMB APPROVAL OMB Number: 3235-0076 Estimated Average burden hours per response: 4.0 1. Issuer's Identity CIK (Filer ID Number) Previous Name(s) None Entity Type Corporation Limited Partnership   Limited Liability Company   General Partnership   Business Trust Other   Name of Issuer   Yuva Biosciences, Inc. Jurisdiction of Incorporation/Organization DELAWARE   Year of Incorporation/Organization Over Five Years Ago Within Last Five Years (Specify Year)   Yet to Be Formed           2. Principal Place of Business and Contact Information Name of Issuer   Yuva Biosciences, Inc. Street Address 1 Street Address 2   1500 1ST AVENUE N   SUITE L 133   BIRMINGHAM   ALABAMA     35203 3. Related Persons Last Name First Name Middle Name Schmergel Greg Street Address 1 Street Address 2   1500 1st Avenue N     Suite L133   Birmingham   ALABAMA   35203   Relationship: Executive Officer Director Promoter Clarification of Response (if Necessary)   Last Name First Name Middle Name Ehrsam Fred Street Address 1 Street Address 2   1500 1st Avenue N     Suite L133   Birmingham   ALABAMA   35203   Relationship: Executive Officer Director Promoter Clarification of Response (if Necessary)   Last Name First Name Middle Name Browne Daniel Street Address 1 Street Address 2   1500 1st Avenue N     Suite L133   Birmingham   ALABAMA   35203   Relationship: Executive Officer Director Promoter Clarification of Response (if Necessary)   4. Industry Group   Agriculture Banking & Financial Services     Commercial Banking     Insurance   Investing     Investment Banking     Pooled Investment Fund   Other Banking & Financial Services   Business Services Energy     Coal Mining     Electric Utilities     Energy Conservation     Environmental Services     Oil & Gas     Other Energy Health Care     Biotechnology     Health Insurance     Hospitals & Physicians     Pharmaceuticals     Other Health Care                         Manufacturing Real Estate   Commercial   Construction   REITS & Finance   Residential Other Real Estate   Retailing Restaurants Technology   Computers   Telecommunications   Other Technology Travel   Airlines & Airports   Lodging & Conventions   Tourism & Travel Services   Other Travel Other        5. Issuer Size Revenue Range Aggregate Net Asset Value Range No Revenues   No Aggregate Net Asset Value   $1 - $1,000,000 $1 - $5,000,000   $1,000,001 - $5,000,000   $5,000,001 - $25,000,000 $5,000,001 - $25,000,000   $25,000,001 - $50,000,000 $25,000,001 - $100,000,000   $50,000,001 - $100,000,000   Over $100,000,000   Over $100,000,000   Decline to Disclose   Decline to Disclose   Not Applicable   Not Applicable   6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply) Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 506(b)         Rule 504 (b)(1)(i) Rule 506(c) Rule 504 (b)(1)(ii) Securities Act Section 4(a)(5) Rule 504 (b)(1)(iii) Investment Company Act Section 3(c)     7. Type of Filing   New Notice Date of First Sale   2026-03-16   First Sale Yet to Occur   Amendment     8. Duration of Offering Does the Issuer intend this offering to last more than one year?   Yes   No     9. Type(s) of Securities Offered (select all that apply) Pooled Investment Fund Interests Equity Tenant-in-Common Securities Debt Mineral Property Securities Option, Warrant or Other Right to Acquire Another Security Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other (describe) Simple Agreements for Future Equity (SAFEs) and equity securities of Issuer into which SAFEs may convert     10. Business Combination Transaction Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?   Yes   No Clarification of Response (if Necessary)       11. Minimum Investment Minimum investment accepted from any outside investor $   0 USD 12. Sales Compensation Recipient   Recipient CRD Number None     (Associated) Broker or Dealer None (Associated) Broker or Dealer CRD Number  None     Street Address 1 Street Address 2             13. Offering and Sales Amounts   Total Offering Amount $ 3000000 USD Indefinite Total Amount Sold $ 1118000 USD Total Remaining to be Sold $ 1882000 USD Indefinite Clarification of Response (if Necessary)      14. Investors Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering       Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter th

View Full Filing

View this D filing on SEC EDGAR